Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163605 | 0.82 | HTR1A (0.41) | HTR1A | |
| SCHEMBL4161926 | 0.82 | TSHR (0.42) | HTR1AMAOBBCHEACHEALDH1A1 | |
| SCHEMBL13851784 | 0.77 | MAPT (0.38) | HTR1AMAOBBCHEACHEALDH1A1 | |
| SCHEMBL4868174 | 0.75 | TDP1 (0.44) | HTR1A | |
| SCHEMBL14268989 | 0.75 | HTR1A (0.45) | HTR1AACHE | |
| SCHEMBL13851862 | 0.73 | TDP1 (0.42) | ALDH1A1 | |
| SCHEMBL8086804 | 0.73 | CYP2E1 (0.58) | HTR1A | |
| SCHEMBL14268974 | 0.72 | TDP1 (0.41) | ALDH1A1 | |
| SCHEMBL4867949 | 0.71 | CYP2E1 (0.43) | HTR1AALDH1A1 | |
| SCHEMBL8093014 | 0.71 | TSHR (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1960413-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060618-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060618-A2 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130225-A1 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS | MGAM, MLX, MYCBP | HTR1A 2758/4885MAOB 1993/4885BCHE 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.